Keywords: PD-1 inhibitor; benign migratory glossitis; cutaneous immune-related adverse events; geographic tongue; hypertrophic lichen planus; immune checkpoint inhibitor; immunotherapy; lichen planus; lichenoid dermatitis; lichenoid inflammation; oral lichen planus; ulcer.